Ongoing Clinical Trials for Viral Myocarditis
Currently, there is 1 ongoing clinical trial investigating treatment options for viral myocarditis. This trial is testing the use of corticosteroid therapy to reduce heart inflammation and improve heart function in patients with this condition. The study is being conducted across multiple European countries.
Clinical trial locations
- Belgium
- Italy
- Slovenia
- Spain
Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function
This clinical trial is investigating whether corticosteroid therapy can improve heart function in patients with acute myocarditis. The condition causes inflammation of the heart muscle, which can reduce the heart’s ability to pump blood effectively. The study uses Solu-Medrone (methylprednisolone sodium succinate), a corticosteroid medication given through an intravenous infusion to reduce inflammation and help the heart recover its function.
Who can participate:
- Adults between 18 and 69 years old
- Patients with reduced heart pumping function, specifically with a left ventricular ejection fraction (LVEF) below 50%
- Those with elevated troponin levels (a heart-related protein) at least three times higher than normal
- Patients with symptoms of heart inflammation that started within the past 3 weeks
- Must be enrolled within 5 days (120 hours) of hospital admission
- For patients aged 46 and older, coronary artery disease must be ruled out unless myocarditis is confirmed through tissue testing
- Must provide informed consent after understanding the study details
Who cannot participate:
- The exclusion criteria were not fully detailed in the available data, but patients must meet all the inclusion requirements to be eligible
What the trial involves:
Participants are randomly assigned to receive either the corticosteroid treatment (Solu-Medrone 125 mg with sodium chloride) or a placebo, which looks identical but contains no active medication. This randomization happens within 5 days of hospital admission. The study aims to determine whether the corticosteroid can improve heart function more effectively than standard treatment alone.
The main goal is to increase the heart’s pumping ability to at least 55% or achieve a 10% improvement in LVEF after 5 days of treatment. Heart function is monitored using echocardiograms (ultrasound images of the heart) and other diagnostic tests throughout the treatment period.
Follow-up evaluations continue at 6 months and 2 years after treatment. These assessments include cardiac magnetic resonance imaging (CMRI) scans and quality of life questionnaires to evaluate long-term heart function and overall patient wellbeing. The study is expected to be completed by May 2028.
Investigational drug:
The study is testing corticosteroid therapy administered intravenously. Corticosteroids work at the molecular level by reducing inflammation and modulating the immune response, which may help alleviate the heart inflammation characteristic of myocarditis. These medications are classified as anti-inflammatory and immunosuppressive agents. In this trial, researchers are evaluating whether this approach can effectively improve heart function in patients with mildly reduced pumping capacity.
Summary
Currently, only one clinical trial is actively recruiting patients with viral myocarditis. This study is being conducted across four European countries: Belgium, Italy, Slovenia, and Spain, indicating a coordinated international effort to understand this condition better.
The trial focuses specifically on corticosteroid therapy as a potential treatment to reduce heart muscle inflammation and improve heart function. The study design includes both short-term monitoring (5 days) and long-term follow-up (up to 2 years), which will provide valuable information about both immediate treatment effects and long-term outcomes for patients.
The research targets patients with mildly reduced heart function who are seen early in their illness, within 5 days of hospital admission. This timing may be important for maximizing the potential benefits of anti-inflammatory treatment. The results of this trial could help doctors better understand whether corticosteroids should be part of standard treatment for patients with acute myocarditis.
